Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.
about
Transfusion transmission of HCV, a long but successful road map to safetyRisk factors for retrovirus and hepatitis virus infections in accepted blood donors.Transfusion-Transmitted InfectionsPrevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors.Assessing the residual risk for transfusion-transmitted infections in the Philippine blood supply.Association of Toll-like receptor polymorphisms with HIV status in North AmericansTransfusion transmitted infections in solid organ transplantation.Performance evaluation of the Elecsys syphilis assay for the detection of total antibodies to Treponema pallidumT-Cell Response to Hepatitis B Core Antigen: Identification of Prior Exposure to and Confirmatory Testing for Screening for Anti-HBc.Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses, and Treponema pallidum infections among blood donors at Shiyan, Central China.Seroprevalence of transfusion-transmissible infectious agents among volunteer blood donors between 2006 and 2012 in Zhejiang, China.Motivating first-time, group O blood donors to return: Rationale and design of a randomized controlled trial of a post-donation telephone interviewRecent Advances in Preventing Adverse Reactions to TransfusionA retrospective analysis of false-positive infectious screening results in blood donorsRisk factors for human immunodeficiency virus infection among Brazilian blood donors: a multicentre case-control study using audio computer-assisted structured interviews.Evaluation of Elecsys Syphilis Assay for Routine and Blood Screening and Detection of Early Infection.Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test.Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety.A brief motivational interview with action and coping planning components enhances motivational autonomy among volunteer blood donors.Utilization and quality of cryopreserved red blood cells in transfusion medicine.Safety of the blood supply.Malaria and blood transfusion: major issues of blood safety in malaria-endemic countries and strategies for mitigating the risk of Plasmodium parasites.Pathogen-reduced platelets for the prevention of bleeding.Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.Trends in age and red blood cell donation habits among several racial/ethnic minority groups in the United States.Prevalence, incidence, and risk factors of human immunodeficiency virus infection in blood donors in the Southeastern United States.Selection strategies for newly registered blood donors in European countries.Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States.Modeling complete removal of risk assessment questions in the USA predicts the risk of HIV exposure in blood recipients could increase despite the use of nucleic acid testing.[Seroprevalence of viral markers among blood donors at the Blood Donor Center of Mohammed V Military Teaching Hospital of Rabat, Morocco].Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation.Transmission of Hepatitis C Virus From Organ Donors Despite Nucleic Acid Test Screening.A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.The epidemiology of human T-cell lymphotropic virus types I and II in Canadian blood donors.Prevalence and factors associated with HCV infection among elderly individuals in a southern Brazilian city.Research on the human virome: where are we and what is next.How do I provide leukapheresis products? Blood center experience and evidence for process improvement.Human T cell lymphotropic virus type 1 infection among U.S. thalassemia patients.The aging of the donor base.
P2860
Q26865471-23A20D69-3352-4EA4-B36F-C0F94E97CC93Q27346471-9A089702-BD1E-4210-ABD6-DEBBBBD18763Q29571219-D86C9703-7EAF-4354-9CED-ABFFBFC3F0E9Q33600962-3C11E669-F30B-432F-974F-1698C89340AAQ34087863-F1F82200-A2B8-4AEE-81A4-87ED77EF010AQ34642208-09484BE8-0085-41CA-87A6-0F4529224803Q34667631-7A115BCA-666C-45D4-8B96-1FD415DA88CEQ34784995-20C301FE-5CC1-4644-91D7-989F890B839DQ35623577-58D0F5EC-BD83-41E4-87D4-79887D0F6295Q36157247-FB134975-C4B9-4B14-B954-D292BFD22442Q36187319-1482429E-D3D3-45D4-97DB-86532D79F6B6Q36540836-1CDE26E9-3B85-4A88-A022-71527CA437AEQ36750167-570C3099-682B-4D99-A3C2-2F08968BAB67Q36788008-E03E021C-0937-4980-A175-83E72FA43DB9Q37070306-B4254BA3-0D8F-42F0-B22F-E4342D534435Q37218607-9D5AD456-A987-47CB-8937-16459678A85EQ37296858-CA15D1F8-0504-45D9-8E31-E4B98EA2C515Q37296863-BBC55ACA-3687-4007-A8B0-FFF99DEEB9E6Q37597801-3CBFC175-85EE-4EB7-B00D-219E999EB8C4Q38282480-036259D3-F2C6-41A0-8D5E-93238AD8F853Q38287590-00E875E9-AF1C-4445-B555-2F76E5802C29Q38623914-B4C9F67F-D887-4270-B091-46C780560AD2Q38653240-65159907-CD7A-401F-B92D-5C440A7E1583Q38803293-055FC75D-04A4-4C02-84CB-646CB6AA01A6Q38859595-EF39FB93-6F9A-4A61-A755-771C05FE6088Q39221818-94B3F034-092C-491A-B49F-EFD241627489Q39306032-188F29E7-A18A-48A7-9451-CE99D7B7010FQ39457208-1DB8BBC7-9CE9-4CE3-809D-0AB5F538DE2DQ40109325-4859334E-A051-451F-B472-A6642A82E5CDQ40293208-8E4BA00B-2B2F-41F4-93CB-20443C2016FFQ40519030-D6AF06DE-045A-4643-8B2B-A95F1B02D8F9Q40611312-43A2F883-DD30-432F-80F9-ED5ABEC8B9BAQ41258015-584A1398-5D38-4308-9DF6-364106C595CFQ42257442-922EEAE0-F704-4824-9F3C-2A7F6041F64AQ42283514-B1120336-2E09-45E7-AEEE-EA9863E53C08Q42283670-C0E3F0C4-946F-48D3-81C8-500D4A498440Q42543729-1DEF2221-077B-42F5-AC3B-D20381F80ED2Q44608267-7086DF9B-2F79-4688-A9EF-33D4457686F8Q45352599-89A47BC8-3CBF-4B9F-A3D2-924930DE455FQ45974983-96BC8C42-0228-4024-BB88-D36C1454C571
P2860
Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Donor testing and risk: curren ...... ts in US allogeneic donations.
@en
Donor testing and risk: curren ...... ts in US allogeneic donations.
@nl
type
label
Donor testing and risk: curren ...... ts in US allogeneic donations.
@en
Donor testing and risk: curren ...... ts in US allogeneic donations.
@nl
prefLabel
Donor testing and risk: curren ...... ts in US allogeneic donations.
@en
Donor testing and risk: curren ...... ts in US allogeneic donations.
@nl
P1476
Donor testing and risk: curren ...... ts in US allogeneic donations.
@en
P2093
Roger Y Dodd
Shimian Zou
P304
P356
10.1016/J.TMRV.2011.07.007
P577
2011-08-25T00:00:00Z